CRISPR, CRSP and Therapeutics

Why CRISPR Therapeutics (CRSP) Soared on Friday?
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other firms that soared on Friday.
Crispr Therapeutics AG (CRSP) Gets a Sell from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Sell rating on Crispr Therapeutics AG (CRSP – Research Report), with
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $56.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock.
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) from In-Line to Outperform. Analyst Price Forecast Suggests 90.46% Upside As of January 28,
Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
CRISPR Therapeutics stock rises following analyst upgrade
CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 gene-editing platform,
CRISPR (CRSP) Upgraded to Outperform by Evercore, Price Target Raised to $99
CRISPR's upcoming trial data and increasing demand for Casgevy drive Evercore's bullish outlook and a higher price target ...
Research Analysts Set Expectations for CRSP Q3 Earnings
Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a report released ...
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.
news.stocktradersdaily10d
(CRSP) Trading Report
Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type a few symbols and Take a Trial. The signals for these will appear ...
Stifel Nicolaus Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)
Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Hosted on MSN2d
Crispr Therapeutics Faces Market Challenges Amidst BPCIA Biosimilar Risks
Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...
Analysts Conflicted on These Healthcare Names: aTyr Pharma (ATYR), Crispr Therapeutics AG (CRSP) and American Well (AMWL)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on aTyr Pharma (ATYR – Research Report), Crispr Therapeutics AG ...